MSH2 and colorectal carcinoma: Similarly, female carriers of MLH1 or MSH2, MLH1, and MSH2 germline mutations had a HR of 13.2 (95% CI = 5.9–29.6), 15.0 (95% CI = 6.4–35.4), and 27.9 (95% CI = 10.1–76.9) for CRC compared to female non-mutation carriers, respectively.